AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$PRGO

Perrigo (PRGO) Q3 2026 Earnings Call Transcript

Perrigo (PRGO) reported Q3 2026 earnings, highlighting operational improvements and a strategic focus on simplifying the business. The company saw sequential improvements in core net sales and operating margins, with a 1.7% decline in sales and a 14.3% operating margin. Perrigo announced the sale of its infant formula business and updated its 2026 outlook, reflecting divestments and market conditions.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 7:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 7:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Perrigo (PRGO) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$PRGONeutralMed
01

Why it matters

The disclosed guidance and operational actions provide fresh data for valuation models and short‑term trading decisions.

02

Market read

Earnings and strategic updates create a modest trading opportunity for PRGO, with potential upside if guidance holds.

03

What to watch

Potential headwinds from retailer inventory positioning and lingering Europe demand softness could limit upside.

Relevance 7/10Novelty 6/10Timing: post‑earnings today

Background

Perrigo's Q3 2026 earnings call outlines a three‑pillar plan, cost‑saving targets, and a strategic divestiture of its infant formula business.

Company-level read

Ticker impact

$PRGONeutralHigh confidence
Context

The transcript provides updated 2026 outlook, announces the infant formula divestiture and $60‑$80M cost‑saving target, all disclosed for the first time.

Expected impact

likely modest upside as market prices in improved margin guidance and divestiture benefits

Evidence & confidence

First‑time disclosure of guidance and strategic actions gives traders a concrete basis to adjust positions.

Market effects

Sector

Improved margins may lift other consumer health and OTC retailers, but Europe softness could weigh sector peers.

Regional

U.S. store‑brand OTC may see slight buying pressure; European consumer‑goods stocks could stay muted.

Global

Limited to consumer health and OTC segments; no broad market move expected.

Counterpoint

What could challenge this read

The divestiture may signal deeper strategic weakness; investors could stay cautious despite guidance lift.

Key entities

  • company
    Perrigo

    Consumer health products maker reporting Q3 2026 results.

Read at source← All news

StoryPerrigo posts Q3 loss, raises FY EPS guidance and announces infant‑formula divestiture

Also covered by

5 outlets

Related articles

$PRGOMed

Perrigo Q3 Earnings Call Highlights

Perrigo (PRGO) reported Q3 earnings with net sales declines in self-care and specialty care segments. Adjusted EPS fell to 61 cents, with a lower tax rate providing some benefit. The company expects 2026 sales declines and adjusted EPS of $2.15-$2.35. Perrigo is divesting infant formula and other businesses to simplify operations and reduce debt. Cash and debt at quarter-end were $437M and $3.3B, respectively.

finance.yahoo.com
$PRGOHigh

Perrigo Sets 2026 All-In Adjusted EPS Outlook at $2.25 to $2.45

Perrigo Company plc set its 2026 adjusted diluted EPS outlook at $2.25 to $2.45, excluding its infant formula unit, which it classified as discontinued operations. Core EPS is expected at $2.15 to $2.35, with core sales declining 2.5% to 3.6% and an adjusted operating margin of 14% to 15%. The company plans to sell the unit to MeridianMade for up to $175 million, with $40 million upfront.

tokenpost.com
$PRGOMed

Perrigo Co PLC (PRGO) (Q3 2026) Earnings Call Highlights: Margin Gains and Share Growth

Perrigo (PRGO) reported Q3 2026 core net sales declined 1.7% YoY, with organic sales down 1.1%. Adjusted gross margin fell 140 bps to 37.9%. The company updated its 2026 outlook downward, citing retailer inventory positioning and European softness. Interim CEO Albert Manzone highlighted share gains, innovation, and e-commerce growth as priorities. The infant formula divestiture is complete, and oral care is under strategic review.

finance.yahoo.com
$PRGOMed

Perrigo Company plc Q3 2026 Earnings Call Summary

Perrigo reported Q3 2026 improvements in core adjusted operating margins (12.8% to 14.3%) due to its Three-S plan. The company is simplifying its portfolio, including divesting the infant formula business, to focus on higher-margin categories. Market share gains in U.S. and European OTC brands were noted, along with e-commerce expansion. Management updated 2026 and 2027 outlooks, emphasizing debt reduction and operational improvements. Q3 results included a $4.5M one-time tariff benefit.

finance.yahoo.com
$PRGOMed

Perrigo 2026: Revenue $988.6M, EPS ($0.2) — 10-Q Summary

Perrigo reported 2026 nine-month net sales of $988.6M, down 5.2% YoY, and a net loss of $27.5M, compared to a net income of $7.5M in the prior year. Diluted loss per share was $0.2, versus earnings of $0.05. The decline was attributed to soft consumer demand, lower retailer inventories, and the sale of the Dermacosmetics business. Perrigo plans to sell its Infant Formula business for up to $175M and expects $80M-$100M in annual savings from a two-year efficiency program.

tradingview.com